logo SIN


Di seguito alcune pubblicazioni ricevute dal prof. Giorgio Cruccu


1. Duloxetine and pregabalin: High-dose monotherapy or their combination? The ‘‘COMBO-DN study’’ – a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Per visualizzare il documento  CLICCA QUI


2. Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: Data from the randomized, double-blind, COMBO-DN study. Per visulizzare il documento CLICCA QUI


3. A mechanism-based classification of pain in multiple sclerosis.

Pharmacological treatment of pain in multiple sclerosis (MS) is challenging due to the many underlying pathophysiological mechanisms. Few controlled trials show adequate pain control in this population. Emerging evidence suggests that pain might be more effectively classified and treated according to symptoms and underlying mechanisms. The new mechanism-based classification we propose here distinguishes nine types of MS-related pain: trigeminal neuralgia and Lhermitte’s phenomenon (paroxysmal neuropathic pain due to ectopic impulse generation along primary afferents), ongoing extremity pain (deafferentation pain secondary to lesion in the spino-thalamocortical pathways), painful tonic spasms and spasticity pain (mixed pains secondary to lesions in the central motor pathways but mediated by muscle nociceptors), pain associated with optic neuritis (nerve trunk pain originating from nervi nervorum), musculoskeletal pains (nociceptive pain arising from postural abnormalities secondary to motor disorders), migraine (nociceptive pain favored by predisposing factors or secondary to midbrain lesions), and treatment-induced pains. Identification of various types of MS-related pain will allow appropriate targeted pharmacological treatment and improve clinical  ractice. Per visualizzare il documento CLICCA QUI


4. Parkinson’s disease related pain: a review of recent findings

In this review we summarize progress in research on Parkinson’s disease-related pain as reported in articles published in the Journal of Neurology in the years 2011 and 2012. Per visualizzare il documento CLICCA QUI


5. Natural history and outcome of 200 outpatients with classical trigeminal neuralgia treated with carbamazepine or oxcarbazepine in a tertiary centre for neuropathic pain.

The guidelines on trigeminal neuralgia management that have been agreed and jointly published by the American Academy of Neurology and the European Federation of Neurological Societies recommend carbamazepine (CBZ) and oxcarbazepine (OXC) as the first-choice medical treatments in patients with trigeminal neuralgia (TN). The aim of this retrospective study was to analyze the natural history of classical trigeminal neuralgia in a large cohort of patients, focusing on drug responsiveness, side effects related to CBZ and OXC, and changes in pain characteristics during the course of disease.

Per visualizzare il documento CLICCA QUI


6. Hyperalgesic activity of kisspeptin in mice

Kisspeptin is a neuropeptide known for its role in the hypothalamic regulation of the reproductive axis. Following the recent description of kisspeptin and its 7-TM receptor, GPR54, in the dorsal root ganglia and dorsal horns of the spinal cord, we examined the role of kisspeptin in the regulation of pain sensitivity in mice.

Per visualizzare il documento CLICCA QUI